Neuromuscular Diseases
13 cases on ALS, myasthenia gravis and myasthenic crisis, GBS/CIDP, muscular dystrophy, periodic paralysis, and spasticity pharmacotherapy — choose a case below to open its full multi-voice debate.
A single patient, newly confirmed with a rare inherited form of ALS. The disagreement isn't about whether tofersen lowers a lab value — it does — it's about whether that's reason enough to start a drug whose own pivotal trial didn't show the thing patients actually feel.
A single patient, well outside the population edaravone's pivotal trial actually enrolled. The disagreement isn't about whether the drug works in early ALS — it's about what that finding means once a wheelchair-bound patient two years past that window asks for it anyway.
A single patient, six months into visible functional decline on standard-dose riluzole, asking for more of it. The disagreement turns on whether that request is actually untested territory.
A single patient, newly diagnosed with generalized myasthenia gravis and already showing real steroid toxicity risk. The disagreement is whether a fast biologic being technically on-label changes where it belongs in the standard treatment sequence.
A single patient, four months into a generalized myasthenia gravis diagnosis with his steroid response already plateauing. The disagreement isn't about whether thymectomy helps — a randomized trial already answered that — it's about when.
Two patients with the same syndrome, treated under genuine equipoise between IVIG and plasma exchange. What changes the answer isn't new evidence — it's a comorbidity profile that turns a theoretical risk into a real one.
A single patient, stable on maintenance IVIG but tired of the infusion-center schedule it demands. The disagreement isn't only about IVIG versus subcutaneous self-administration — it's about whether anyone has actually tested whether he needs immunoglobulin at all.
A newly diagnosed 5-year-old boy, still ambulatory, about to start standard corticosteroid therapy. The disagreement is which drug — and how much the family's own cost constraint should weigh against a modest functional advantage.
A 7-year-old boy, genetically eligible for a therapy built for his exact mutation. The disagreement isn't about the mechanism — it's about whether the confirmatory trials required by the drug's own accelerated approval have actually shown it helps.
A single patient with a clear family history of episodic weakness and a genetic panel still weeks from returning. The disagreement is whether to treat the likely diagnosis now or wait for confirmation of a gene that could make the same drug worse, not better.
A single patient in the ICU with myasthenic crisis and a swinging blood pressure. The disagreement isn't the same as the drug-selection question in Guillain-Barré syndrome — it's a distinct acute setting where a planned thymectomy and active hemodynamic instability pull in opposite directions.
A single patient with progressive lower-limb spasticity in a specific, gait-driving pattern layered over milder diffuse tone. The disagreement is whether a targeted injection or a systemic drug actually matches what her exam shows.
A single patient with post-spinal-cord-injury spasticity already near his maximal tolerated oral dose. The disagreement is whether a more effective delivery route is worth a rare but life-threatening withdrawal risk for a patient with real gaps in his own follow-up.